Skip to main content
OpenTrials

Clinical trial condition

Demyelinating Diseases

Explore clinical trials studying Demyelinating Diseases. Study availability and eligibility vary by location and protocol.

2,934 public trials 459 recruiting studies
Refine in advanced search Browse all conditions

Demyelinating Diseases trial results

Completed

Long-term Follow-up of Fingolimod Phase II Study Patients

NCT02307838

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Novartis Investigative Site Ottawa, Ontario, Canada
  • Novartis Investigative Site Toronto, Ontario, Canada
  • Novartis Investigative Site Montreal, Quebec, Canada
  • Novartis Investigative Site Montreal, Quebec, Canada
View all 26 locations
View Trial Details
Completed

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT02776072

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +4 more
Locations
  • Research Site Homewood, Alabama, United States
  • Research Site Gilbert, Arizona, United States
  • Research Site Hanford, California, United States
  • Research Site Modesto, California, United States
View all 121 locations
View Trial Details
Completed

Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis

NCT00469378

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +4 more
Locations
  • GSK Investigational Site Brussels, Belgium
  • GSK Investigational Site Brussels, Belgium
  • GSK Investigational Site Olomouc, Czechia
  • GSK Investigational Site Prague, Czechia
View Trial Details
Completed

Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis

NCT01480076

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +4 more
Locations
  • Research Site Concord, New South Wales, Australia
  • Research Site Kogarah, New South Wales, Australia
  • Research Site Liverpool, New South Wales, Australia
  • Research Site New Lambton Heights, New South Wales, Australia
View all 59 locations
View Trial Details
Completed

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis

NCT01156311

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Gilbert, Arizona, United States
  • Research Site Phoenix, Arizona, United States
  • Research Site Danbury, Connecticut, United States
  • Research Site Atlanta, Georgia, United States
View all 16 locations
View Trial Details
Completed

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients

NCT00871780

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Biogen Idec Investigative Site Liège, Belgium
  • Biogen Idec Investigative Site Puebla City, Mexico
  • Biogen Idec Investigative Site Bialystok, Poland
  • Biogen Idec Investigative Site Bydgoszcz, Poland
View all 15 locations
View Trial Details
Completed

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

NCT01333501

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +9 more
Locations
  • Novartis Investigative Site Alzenau in Unterfranken, Germany
  • Novartis Investigative Site Bamberg, Germany
  • Novartis Investigative Site Leipzig, Germany
  • Novartis Investigative Site Würzburg, Germany
View all 26 locations
View Trial Details

Related conditions